How is the biopharmaceutical sector evolving, and where are opportunities for advancement? The biopharma sector has undergone significant change over the last 30 years, and it’s set to continue seeing steady change as manufacturing logistics shift to meet patient needs and global policies. In this article, Brandon Pence (left) – the President and Chief Operating Officer of FUJIFILM Biosciences (CA, USA), a global life sciences provider of innovative products for advancing healthcare – takes us behind the scenes of biopharma to explore how it’s evolving and the logistical challenges that come with that evolution. Drawing from experience Having spent my entire career serving the biopharmaceutical sector, it is fascinating to look back and take stock of just how far our industry has come over the past 30 years. From my start as a scientist in bioprocessing R&D teams, to advancing innovation and strategy as a global business leader, I have a deep appreciation of all the hard work that has brought us to this point as an industry today. When a new biologic reaches a patient, a multitude of upstream decisions – including media formulation, materials and manufacturing design, as well as complex quality topics and supply chain orchestration – have already shaped its success. In this column, I’d like to highlight how we’ve kept this critical ecosystem moving and some opportunities for future advancement. From the initial rise of biologic therapies to the unprecedented battle against a global pandemic and the race for vaccine development, the biopharmaceutical sector…
